Lowering prescription drug costs and health care costs are among the goals of the Inflation Reduction Act. While changes will not take effect until 2025, what can the biopharmaceutical industry expect?
I am so happy to be working with a group of people with diverse backgrounds, professional mindset, and shared mission. The strongly unified leadership team at STATinMED has been moving toward excellence.
What’s impressive now is our growing clientele within the broader healthcare arena—there are many companies outside of pharma reaching to us for insights about products, services, and providers. Data-driven business intelligence is helping healthcare.
Want to learn more about STATinMED and the power of RWD Insights? Here we share some common questions, with answers about our data source and approach. Is your data source HIPAA-compliant? Yes, our data source is de-identified, tokenized, and meets the...
Study Purpose and Population Epidemiology of rare diseases is important for clinicians to consider, as prevalence and incidence inform the healthcare community about likelihood of disease within an at-risk population. Studies in epidemiology also help to support...
Clinically eligible lives data powered by STATinMED RWD Insights offer accurate and timely TRUE market opportunity, where detailed utilization management policies are managed, and contracts are negotiated.